Welcome to our dedicated page for Lyra Therapeutics SEC filings (Ticker: LYRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lyra Therapeutics, Inc. (Nasdaq: LYRA) SEC filings page on Stock Titan provides access to the company’s public reports and current reports filed with the U.S. Securities and Exchange Commission. Lyra identifies itself in these filings as a clinical-stage biotechnology company developing long-acting, anti-inflammatory sinonasal implants for chronic rhinosinusitis (CRS), with its common stock listed on The Nasdaq Capital Market under the symbol LYRA.
Through Lyra’s Forms 10-K and 10-Q, readers can review detailed financial statements, including collaboration revenue, research and development expenses related to the ENLIGHTEN Phase 3 clinical program for LYR-210, general and administrative costs, restructuring charges, and cash and cash equivalents balances. These periodic reports also describe the company’s status as a clinical-stage entity with no approved products and discuss risks such as ongoing losses, funding needs, and dependence on clinical trial outcomes.
Current reports on Form 8-K document material events that are important for understanding LYRA’s situation. Examples include notices from The Nasdaq Stock Market regarding compliance with listing requirements, such as minimum bid price and stockholders’ equity thresholds; details of a registered direct offering and concurrent private placement of warrants; and changes in board and executive roles. Other 8-K filings reference the posting of corporate presentations that discuss LYR-210 and the ENLIGHTEN clinical program.
For those interested in clinical and strategic developments, Lyra’s filings and attached exhibits often cross-reference press releases that summarize ENLIGHTEN 2 Phase 3 results, pooled analyses in patients with nasal polyps, and regulatory interactions with the U.S. Food and Drug Administration. More recent corporate updates, including the decision by Lyra’s Board of Directors to suspend further development of LYR-210 and cease product development operations, are reflected in company disclosures and provide important context for interpreting financial and risk disclosures.
On Stock Titan, these SEC filings are updated as new documents are posted to EDGAR. AI-powered tools can help readers quickly identify key sections in lengthy reports, such as risk factors, management’s discussion and analysis, restructuring notes, and disclosures related to Nasdaq listing status, financing agreements, and strategic alternatives under consideration.
Lyra Therapeutics, Inc. reported that on February 23, 2026 it received a notice of default from RVAC Medicines (US), Inc. under its sublease for office space in Waltham, Massachusetts. The default stems from unpaid rent invoices from the master landlord totaling
The company previously disclosed that it is ceasing operations and preparing for a wind-down while pursuing strategic options, and has been trying to settle obligations, including lease liabilities, outside a bankruptcy process. Lyra had proposed terminating the sublease with a premises surrender date of January 31, 2026, but no agreement was reached before rent payments stopped.
Lyra states it is continuing to evaluate options regarding the sublease and other outstanding obligations as part of its wind-down. It cautions that there can be no assurance it will successfully negotiate a termination or otherwise resolve these obligations outside of a bankruptcy process, highlighting significant uncertainty around remaining liabilities.
Lyra Therapeutics, Inc. reports that Nasdaq has moved to delist its common stock after determining under Listing Rule 5101 that the company is a “public shell” without an operating business. Nasdaq cited Lyra’s prior decision to suspend development of its lead product candidate LYR-210 and a reduction in force that terminated nearly all employees, including shifting the CEO and CFO to consultant roles.
Nasdaq also asserted Lyra has not met the minimum $2,500,000 stockholders’ equity requirement in Listing Rule 5550(b), despite an earlier compliance extension and Lyra’s request for more time to complete a financing. Lyra has requested a hearing before a Nasdaq Hearings Panel, which temporarily stays any suspension and Form 25-NSE filing, but there is no assurance its appeal will succeed.
Lyra Therapeutics insider plans a modest stock sale under Rule 144. A person for whose account the securities are to be sold, identified elsewhere as Maria Palasis, filed to sell 1895 shares of Lyra common stock on or about 01/27/2026 through Fidelity Brokerage Services LLC on the NASDAQ market. The aggregate market value of the planned sale is 3248.03, and the filing notes that 1774882 common shares are outstanding.
The 1895 shares to be sold were acquired on 01/12/2026 via restricted stock vesting from the issuer as compensation, with the same date listed for payment. The filer also reports that Maria Palasis sold 1702 Lyra common shares on 01/06/2026 for gross proceeds of 5725.36 during the past three months. By signing, the seller represents they are not aware of undisclosed material adverse information about Lyra’s operations.
Lyra Therapeutics, Inc. received a Schedule 13G filing showing that Sabby Volatility Warrant Master Fund, Ltd., Sabby Management, LLC, and Hal Mintz together report beneficial ownership of 175,158 shares of Lyra common stock. This position represents 9.87% of the outstanding common shares as of the event date. The filing states that all three reporting persons share both voting and dispositive power over these shares and have no sole voting or dispositive authority.
The filers certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Lyra Therapeutics, describing the position as a passive investment under Schedule 13G.
Lyra Therapeutics disclosed a major restructuring centered on suspending further development of LYR-210, its lead drug candidate for chronic rhinosinusitis, and implementing a cost reduction plan that includes a workforce reduction affecting substantially all remaining employees, effective January 12, 2026. The company expects to incur charges related to severance, benefits and associated costs, and plans to amend this report once it can estimate those amounts.
In connection with the plan, the employment of CEO, President and Chair Dr. Maria Palasis and CFO and Treasurer Jason Cavalier was terminated on January 9, 2026, with each moving to a consulting role supporting the pursuit of strategic alternatives and continuing as principal executive and principal financial officer, respectively. Their consulting agreements provide monthly fees of $78,125 for Dr. Palasis and $55,555.50 for Mr. Cavalier, change-of-control vesting for time-based restricted stock units, and potential transaction bonuses if the change-in-control purchase price exceeds $5,000,000.
The board has decided to cease product development operations while continuing to evaluate strategic alternatives, assisted by SSG Capital Advisors, LLC. As of September 30, 2025, Lyra held approximately $22.1 million in cash, cash equivalents and short-term investments and currently expects its cash runway to extend to the third quarter of 2026.
Lyra Therapeutics, Inc. Chief Financial Officer Jason Cavalier reported a small, pre-arranged sale of 769 shares of common stock. The sale occurred on 01/06/2026 at a price of $3.364 per share under transaction code "S." According to the filing, the shares were sold to cover taxes triggered by the vesting of restricted stock units under a mandatory Rule 10b5-1 trading instruction adopted on January 1, 2025.
Following this tax-withholding sale, Cavalier beneficially owns 518,547 shares of Lyra Therapeutics common stock in direct form. The transaction is characterized as administrative in nature, tied to equity award vesting rather than an open-market discretionary sale.
Lyra Therapeutics, Inc. reported an insider tax-related share sale by its President & CEO, Maria Palasis. On 01/06/2026, she sold 1,702 shares of Lyra common stock at a price of $3.364 per share. The filing states that these shares were sold to cover taxes due upon the vesting of restricted stock units, under a mandatory Rule 10b5-1 trading instruction adopted on January 1, 2025. After this transaction, she beneficially owned 1,096,733 shares of Lyra common stock directly.
Lyra Therapeutics (LYRA): insider transactions reported. Perceptive-affiliated entities disclosed multiple open-market sales of common stock on 11/11/2025, 11/12/2025, and 11/13/2025. Reported weighted average prices were $4.3146, $4.0594, and $3.9001, respectively.
Following these transactions, the filing shows Perceptive Life Sciences Master Fund, Ltd. with 124,859 shares and Perceptive LS (A), LLC with 14,026 shares, each held indirectly. The filing notes that prices reflect weighted averages over multiple trades and that the reporting persons disclaim beneficial ownership beyond their indirect pecuniary interests.
Lyra Therapeutics (LYRA) filed its Q3 2025 10‑Q, reporting a narrower quarter but ongoing strain. Collaboration revenue was $25 thousand, while operating expenses fell to $6.3 million, reflecting prior restructuring. The company posted a net loss of $6.0 million for the quarter and $22.0 million year‑to‑date.
Cash and cash equivalents were $22.1 million as of September 30, 2025, down from $40.6 million at year‑end. Total assets were $43.7 million and stockholders’ deficit was $4.3 million, compared with equity of $11.6 million at December 31, 2024. Net cash used in operations was $22.8 million for the nine months ended September 30, 2025.
Management disclosed “substantial doubt” about the company’s ability to continue as a going concern. Lyra received a Nasdaq notice in August 2025 for not meeting the $2.5 million stockholders’ equity requirement; Nasdaq accepted a plan with a deadline of December 31, 2025. The company effected a 1‑for‑50 reverse stock split on May 27, 2025 and completed a June 2025 financing for $5.0 million gross. Shares outstanding were 1,774,882 as of November 7, 2025.
Lyra Therapeutics (LYRA): Director-affiliated entities reported sales of common stock. A Form 4 shows multiple sales on 11/06/2025, 11/07/2025, and 11/10/2025 at weighted average prices of $5.1799, $4.7467, and $4.5398, respectively. The transactions were reported as indirect holdings tied to Perceptive Life Sciences Master Fund, Ltd. and Perceptive LS (A), LLC.
Following these transactions, beneficially owned shares reported were 166,101 for the Master Fund and 18,659 for Perceptive LS. Footnotes note prices are weighted averages with individual trade prices available upon request. Reporting persons include Perceptive Advisors, LLC, Perceptive LS GP, LLC, and Joseph Edelman, who is listed as a director and reports indirect ownership as described.